Advertisement
Mayo Clinic Proceedings Home

Pneumocystis carinii Pneumonia in Patients Without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy

  • Author Footnotes
    * Current address: Jacksonville, Florida.
    Steven H. Yale
    Footnotes
    * Current address: Jacksonville, Florida.
    Affiliations
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota
    Search for articles by this author
  • Andrew H. Limper
    Correspondence
    Address reprint requests to Dr. A. H. Limper, Thoracic Diseases Research Unit, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905
    Affiliations
    Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota
    Search for articles by this author
  • Author Footnotes
    * Current address: Jacksonville, Florida.

      Objective

      To determine the clinical spectrum of immunosuppressive conditions and systemic corticosteroid therapy associated with the development of Pneumocystis carinii pneumonia in a consecutive series of patients without acquired immunodeficiency syndrome (AIDS).

      Design

      We retrospectively analyzed a consecutive series of 116 patients without AIDS who were assessed at Mayo Medical Center for a first episode of P. carinii pneumonia between 1985 and 1991.

      Methods

      Medical records were examined to determine underlying immunosuppressive disorders, premorbid corticosteroid dosage and duration of therapy, associated infections, and subsequent respiratory failure and in-hospital mortality.

      Results

      Conditions associated with a first episode of P. carinii pneumonia were hematologic malignant disorders (30.2%), organ transplantation (25.0%), inflammatory disorders (22.4%), solid tumors (12.9%), and miscellaneous conditions (9.5%). Regardless of the associated underlying disease, corticosteroids had been administered systemically in 105 patients (90.5%) within 1 month before the diagnosis of P. carinii pneumonia. The median daily corticosteroid dose was equivalent to 30 mg of prednisune; however, 25% of patients had received as little as 16 mg of prednisone daily. The median duration of corticosteroid therapy was 12 weeks before the development of pneumonia; however, P. carinii pneumonia developed after 8 weeks or less of corticosteroid therapy in 25% of these patients. Respiratory failure occurred in 43%, and in-hospital mortality was 34% for patients with P. carinii pneumonia in conditions other than AIDS.

      Conclusion

      Although these results do not suggest that premorbid administration of corticosteroids is the only factor that contributes to the development of P. carinii pneumonia in these patients, they show that, in this large consecutive series, systemic corticosteroid therapy, even in moderate doses, was administered to most patients during the month preceding the onset of P. carinii pneumonia. Consideration should be given to instituting P. carinii prophylaxis (when not contraindicated) in patients for whom prolonged systemic corticosteroid therapy is prescribed.

      Abbreviations:

      AIDS (acquired immunodeficiency syndrome), BAL (bronchoalveolar lavage), HIV (human immunodeficiency virus)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Walzer PD
        • Perl DP
        • Krogstad DJ
        • Rawson PG
        • Schultz MG
        Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features.
        Ann Intern Med. 1974; 80: 83-93
        • Peters SG
        • Prakash UBS
        Pneumocystis carinii pneumonia: review of 53 cases.
        Am J Med. 1987; 82: 73-78
        • Hughes WT
        Pneumocystis carinii pneumonia.
        N Engl J Med. 1977; 297: 1381-1383
        • Sepkowitz KA
        Pneumocystis carinii pneumonia in patients without AIDS.
        Clin Infect Dis. 1993; 17: S416-S422
        • Limper AH
        • Offord KP
        • Smith TF
        • Martin II, WJ
        Pneumocystis carinii pneumonia: differences in lung parasite number and inflammation in patients with and without AIDS.
        Am Rev Respir Dis. 1989; 140: 1204-1209
        • Murray JF
        • Mills J
        Pulmonary infectious complications of human immunodeficiency virus infection. Part II.
        Am Rev Respir Dis. 1990; 141: 1582-1598
        • Safrin S
        Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
        Semin Respir Infect. 1993; 8: 96-103
        • Kovacs JA
        • Hiemenz JW
        • Macher AM
        • Stover D
        • Murray HW
        • Shelhamer J
        • et al.
        Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.
        Ann Intern Med. 1984; 100: 663-671
        • Wachter RM
        • Luce JM
        • Safrin S
        • Berrios DC
        • Charlebois E
        • Scitovsky AA
        Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure.
        JAMA. 1995; 273: 230-235
        • Montaner JS
        • Lawson LM
        • Levitt N
        • Belzberg A
        • Schechter MT
        • Ruedy J
        Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS).
        Ann Intern Med. 1990; 113: 14-20
        • Bozzette SA
        • Sattler FR
        • Chiu J
        • Wu AW
        • Gluckstein D
        • Kemper C
        • et al.
        A controlled trial of early adjuvant treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
        N Engl J Med. 1990; 323: 1451-1457
        • Gagnon S
        • Boota AM
        • Fischl MA
        • Baier H
        • Kirksey OW
        • La Voie L
        Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial.
        N Engl J Med. 1990; 323: 1444-1450
        • Sepkowitz KA
        • Brown AE
        • Telzak EE
        • Gottlieb S
        • Armstrong D
        Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.
        JAMA. 1992; 267: 832-837
        • Walzer PD
        Experimental models for Pneumocystis carinii infections.
        Lung Biol Health Dis. 1984; 22: 7-76
        • Rifkind D
        • Faris TD
        • Hill Jr, RB
        Pneumocystis carinii pneumonia: studies on the diagnosis and treatment.
        Ann Intern Med. 1966; 65: 943-956
        • Slivka A
        • Wen PY
        • Shea WM
        • Loeffler JS
        Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors.
        Am J Med. 1993; 94: 216-219
        • Mahan CT
        • Sale GE
        Rapid methenamine silver stain for Pneumocystis and fungi.
        Arch Pathol Lab Med. 1978; 102: 351-352
        • Kim YK
        • Parulekar S
        • Yu PK
        • Pisani RJ
        • Smith TF
        • Anhalt JP
        Evaluation of calcofluor white stain for detection of Pneumocystis carinii.
        Diagn Microbiol Infect Dis. 1990; 13: 307-310
        • Haynes Jr, RC
        • Murad F
        Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis.
        in: Gilman AG Goodman LS Gilman A Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 6th ed. Macmillan, New York1980: 1466-1496
        • DeVita Jr, VT
        • Goodell B
        • Hubbard S
        • Geelhoed GW
        • Young RC
        Pneumocystis pneumonia in patients with cancer: clinical setting.
        Natl Cancer Inst Monogr. 1976; 43: 41-47
        • Masur H
        • Lane HC
        • Kovacs JA
        • Allegra CJ
        • Edman JC
        Pneumocystis pneumonia: from bench to clinic.
        Ann Intern Med. 1989; 111: 813-826
        • Walzer PD
        • LaBine M
        • Redington TJ
        • Cushion MT
        Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia.
        J Immunol. 1984; 133: 2502-2508
        • Siminski J
        • Kidd P
        • Phillips GD
        • Collins C
        • Raghu G
        Reversed helper/suppressor T-lymphocyte ratio in bron-choalveolar lavage fluid from patients with breast cancer and Pneumocystis carinii pneumonia.
        Am Rev Respir Dis. 1991; 143: 437-440
        • Shellito J
        • Suzara VV
        • Blumenfeld W
        • Beck JM
        • Steger HJ
        • Ermak TH
        A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.
        J Clin Invest. 1990; 85: 1686-1693
        • Masur H
        • Jones TC
        The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.
        J Exp Med. 1978; 147: 157-170
        • Von Behren LA
        • Pesanti EL
        Uptake and degradation of Pneumocystis carinii by macrophages in vitro.
        Am Rev Respir Dis. 1978; 118: 1051-1059
        • Hidalgo HA
        • Helmke RJ
        • German VF
        • Mangos JA
        Pneumocystis carinii induces an oxidative burst in alveolar macrophages.
        Infect Immun. 1992; 60: 1-7
        • Hoffman OA
        • Standing JE
        • Limper AH
        Pneumocystis carinii stimulates tumor necrosis factor-α release from alveolar macrophages through a β-glucan-mediated mechanism.
        J Immunol. 1993; 150: 3932-3940
        • Castro M
        • Morgenthaler TI
        • Hoffman OA
        • Standing JE
        • Rohrbach MS
        • Limper AH
        Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages.
        Am J Respir Cell Mol Biol. 1993; 9: 73-81
        • U. S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients With Human Immunodeficiency Virus Infection
        Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.
        J Acquir Immune Defic Syndr. 1993; 6: 46-55
        • Gallant JE
        • Moore RD
        • Chaisson RE
        Prophylaxis for opportunistic infections in patients with HIV infection.
        Ann Intern Med. 1994; 120: 932-944
        • Centers for Disease Control
        Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus.
        MMWR Morb Mortal Wkly Rep. 1992; 41: l-11
        • Bozzette SA
        • Finkelstein DM
        • Spector SA
        • Frame P
        • Powderly WG
        • He W
        • for the NIAID AIDS Clinical Trials Group
        • et al.
        A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection.
        N Engl J Med. 1995; 332: 693-699
        • Hughes WT
        • Rivera GK
        • Schell MJ
        • Thornton D
        • Lott L
        Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis.
        N Engl J Med. 1987; 316: 1627-1632
        • Kuller J
        • First MR
        • D'Achiardi R
        • Munda R
        Pneumocystis carinii pneumonia in renal transplant recipients.
        Am J Nephrol. 1982; 2: 312-315
        • Kramer MR
        • Stoehr C
        • Lewiston NJ
        • Starnes VA
        • Theodore J
        Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation-how effective and for how long?.
        Transplantation. 1992; 53: 586-589
        • Colombo JL
        • Sammut PH
        • Langnas AN
        • Shaw Jr, BW
        The spectrum of Pneumocystis carinii infection after liver transplantation in children.
        Transplantation. 1992; 54: 621-624

      Linked Article

      • Pneumocystis carinii Pneumonia Without Acquired Immunodeficiency Syndrome: Who Should Receive Prophylaxis?
        Mayo Clinic ProceedingsVol. 71Issue 1
        • Preview
          Pathogens that cannot be cultivated rapidly and reliably cause myriad difficulties for patients and physicians. Treponema pailidum, Borrelia burgdorferi, and Mycobacterium tuberculosis are familiar examples; the diagnosis and natural history of syphilis and Lyme disease, as well as a means of monitoring response to therapy, remain puzzling and even mysterious. Meanwhile, an entire cottage industry of masks, respirators, air sterilizers, and related equipment has developed around the numerous uncertainties that surround the diagnosis of tuberculosis.
        • Full-Text
        • PDF